Granulocyte Colony-Stimulating Factor Prior to Nonmyeloablative Irradiation Decreases Murine Host Hematopoietic Stem Cell Function and Increases Engraftment of Donor Marrow Cells
- 8 March 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 25 (6) , 1578-1585
Abstract
The use of nonmyeloablative conditioning prior to bone marrow transplantation is an important component of transplantation-based therapies for nonmalignant blood diseases. In this study, treatment of recipient mice with granulocyte colony-stimulating factor (G-CSF) prior to low-dose total body irradiation (LD-TBI) enhanced long-term engraftment of freshly isolated congenic marrow 1.5- to 2-fold more than treatment with LD-TBI alone. This combined regimen was also evaluated in a mouse model of X-linked chronic granulomatous disease (X-CGD), where neutrophils have a defective NADPH oxidase due to genetic deletion of the gp91phox subunit. Long-term engraftment of male X-CGD bone marrow cells cultured ex vivo for retroviral transduction of gp91phox was enhanced by ∼40% when female X-CGD recipients were pretreated with G-CSF prior to 300 cGy. These data confirm that sequential treatment with G-CSF and LD-TBI prior to transplantation increases long-term engraftment of donor marrow, and they extend this approach to transplantation of murine donor marrow cultured ex vivo for gene transfer. Additional studies showed that the administration of G-CSF prior to LD-TBI did not alter early homing of donor marrow cells. However, the combined regimen significantly decreased the content of long-term repopulating cells in recipient marrow compared with LD-TBI alone, as assessed in competitive assays, which may contribute to the enhanced engraftment of donor marrow cells. Disclosure of potential conflicts of interest is found at the end of this article.Keywords
This publication has 34 references indexed in Scilit:
- Mobilization as a preparative regimen for hematopoietic stem cell transplantationBlood, 2006
- Survival of the fittest: in vivo selection and stem cell gene therapyBlood, 2006
- Correction of murine hemophilia a by hematopoietic stem cell gene therapyMolecular Therapy, 2005
- Soluble factor cross-talk between human bone marrow-derived hematopoietic and mesenchymal cells enhances in vitro CFU-F and CFU-O growth and reveals heterogeneity in the mesenchymal progenitor cell compartmentBlood, 2005
- A murine model of antimetabolite-based, submyeloablative conditioning for bone marrow transplantation: biologic insights and potential applicationsExperimental Hematology, 2004
- Long-Term Interferon- Therapy for Patients with Chronic Granulomatous DiseaseClinical Infectious Diseases, 2004
- Gene therapy for chronic granulomatous diseaseExpert Opinion on Biological Therapy, 2004
- Distribution of marrow repopulating cells between bone marrow and spleen early after transplantationBlood, 2003
- Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in miceBlood, 2003
- Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative ConditioningScience, 2002